Genetics may help explain why results from weight-loss jabs vary, say scientists科學家表示，基因可能有助於解釋為何減重針的效果因人而異
聆聽課程
0:00
0:00
#1
New clinical research suggests that gene variations may partly account for why weight-loss treatments work remarkably well for some patients yet prove less effective for others.
新的臨床研究顯示，基因變異可能在一定程度上解釋了為什麼減重療程對某些患者效果顯著，但對其他患者則效果較差。
#2
Scientists have identified two specific genetic variants linked to gut hormone pathways that appear to influence both treatment outcomes and side-effects associated with popular obesity medications.
科學家已鑑定出兩個與腸道激素途徑相關的特定基因變異，這些變異似乎會影響治療效果以及與熱門肥胖藥物相關的副作用。
#3
The findings, published in the journal Nature, draw on data from nearly 28,000 patients prescribed GLP1 receptor agonist drugs.
這項發表於《自然》期刊的研究結果，利用了近 28,000 名被開立 GLP1 受體激動劑藥物患者的數據。
#4
These medications, including semaglutide, marketed as Wegovy, and tirzepatide, sold under the brand name Mounjaro, mimic natural gut hormones that regulate appetite and insulin release.
這些藥物，包括以 Wegovy 為名銷售的 semaglutide，以及以品牌名稱 Mounjaro 販售的 tirzepatide，模仿了調節食慾和胰島素釋放的天然腸道激素。
#5
Millions of people worldwide now rely on such drugs to manage obesity, yet the reasons behind individual variation in response have long remained elusive.
全球數百萬人現在依賴此類藥物來控制肥胖，然而，反應中個體差異背後的原因長期以來一直難以捉摸。
#6
Researchers from 23andMe, a nonprofit medical research institute, reported that one variant, known as rs10305420, was associated with slightly greater weight loss among carriers.
來自非營利醫學研究機構 23andMe 的研究人員報告稱，一種名為 rs10305420 的變體與攜帶者體重減輕幅度略大有關。
#7
Another variant, rs1800437, was linked to nausea and vomiting in patients taking tirzepatide, though it bore no significant correlation with the amount of weight lost.
另一種變體 rs1800437 與服用替澤帕肽（tirzepatide）患者出現的噁心和嘔吐有關，儘管它與體重減輕的量並無顯著相關性。
#8
These discoveries underscore how subtle genetic differences may shape an individual's physiological response to medication.
這些發現強調了細微的基因差異如何可能塑造個人對藥物的生理反應。
#9
Should these preliminary findings be validated by larger studies, they could pave the way for a more personalised approach to obesity treatment.
若這些初步發現能經由更大規模的研究證實，它們將能為更個人化的肥胖治療方式鋪路。
#10
Clinicians have long emphasised that a one-size-fits-all strategy rarely yields optimal outcomes in chronic disease management.
臨床醫生長期以來一直強調，一體適用的策略在慢性病管理中鮮少能產生最佳成效。
#11
Were physicians able to screen patients' genetic profiles before prescribing weight-loss drugs, they might anticipate who would benefit most and who might experience adverse reactions.
若醫生能在開立減重藥物前篩檢患者的基因圖譜，他們或許就能預見誰會獲益最多，以及誰可能會產生不良反應。
#12
Nonetheless, experts have cautioned that the overall impact of genetics on drug response appears modest at this stage.
儘管如此，專家們警告說，遺傳學對藥物反應的整體影響在現階段看來並不明顯。
#13
The interplay between genetic predisposition, lifestyle factors, and metabolic health remains extraordinarily complex.
基因傾向、生活方式因素與代謝健康之間的相互作用仍然極其複雜。
#14
Further large-scale studies will be indispensable if researchers are to develop reliable genetic screening tools for clinical use in the foreseeable future.
若研究人員要在可預見的未來開發出可靠的基因篩檢工具，進一步的大規模研究將是不可或缺的。